Trial Failure Shock: Recent discussions on social media have been dominated by the dramatic collapse of Mereo BioPharma's stock price following the announcement of failed Phase 3 trials. The ORBIT and COSMIC studies for setrusumab in osteogenesis imperfecta missed their primary endpoints, leading to a reported drop of over 90% in share value. Many are expressing shock at the sudden downturn after high expectations for the drug.
Analyst Downgrades: Conversations also highlight analyst reactions, with significant price target cuts from as high as $8 to as low as $1. There’s a sense of uncertainty as some note the company still holds a cash reserve of around $48 million, though concerns about future growth persist. The tone reflects a mix of disappointment and speculation about potential next steps.
Market Volatility: Finally, social media is buzzing with warnings about the stock being a high-risk play right now. Posts describe it as a 'falling knife' with no clear bottom in sight, fueled by massive trading volume during the sell-off. The community seems split between those seeing it as a cautionary tale and others watching for a possible rebound.
Note: This discussion summary was generated from an AI condensation of post data.
Mereo BioPharma Hedge Fund Activity
We have seen 37 institutional investors add shares of Mereo BioPharma stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 6,710,429 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,823,483
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,813,550 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7,855,913
- MORGAN STANLEY added 2,560,970 shares (+326.1%) to their portfolio in Q3 2025, for an estimated $5,275,598
- ABERDEEN GROUP PLC added 2,509,827 shares (+82.9%) to their portfolio in Q3 2025, for an estimated $5,170,243
- CITADEL ADVISORS LLC added 2,410,973 shares (+317.0%) to their portfolio in Q3 2025, for an estimated $4,966,604
- JANUS HENDERSON GROUP PLC removed 1,398,462 shares (-7.9%) from their portfolio in Q3 2025, for an estimated $2,880,831
- BLUE OWL CAPITAL HOLDINGS LP added 1,250,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,575,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Mereo BioPharma Analyst Ratings
Wall Street analysts have issued reports on $MREO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/29/2025
- Needham issued a "Buy" rating on 12/22/2025
To track analyst ratings and price targets for Mereo BioPharma, check out Quiver Quantitative's $MREO forecast page.
Mereo BioPharma Price Targets
Multiple analysts have issued price targets for $MREO recently. We have seen 4 analysts offer price targets for $MREO in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- Maury Raycroft from Jefferies set a target price of $0.5 on 12/30/2025
- Julian Harrison from BTIG set a target price of $1.0 on 12/29/2025
- Gil Blum from Needham set a target price of $5.0 on 12/22/2025
- Priyanka Grover from JP Morgan set a target price of $8.0 on 08/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
